Condition: Hyperandrogenism · Polycystic Ovary Syndrome · Puberty · Sponsor: University of Virginia
The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).
This description comes directly from the study's public registry record.
Melissa Gilrain, MS · 434-243-6911 · mg7zb@uvahealth.org
Christine Burt Solorzano, M.D. · 434-243-6911 · cmb6w@uvahealth.org
Always discuss trial participation with your own doctor first.
| University of Virginia Clinical Research Unit | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03068910